Investigating Significant Health Trends in Idiopathic Pulmonary Fibrosis

Study Overview
=================
Brief Summary
-----------------
Idiopathic pulmonary fibrosis (IPF), a manifestation of chronic progressive fibrosing interstitial pneumonia,ia a rare disease. Current treatment options are limited, and the mean survival time of the newly diagnosed (mostly elderly) patients is only about 2-3 years. As in Europe data are limited on the characteristics and management of such patients, INSIGHTS-IPF was initiated as a new registry that documents newly diagnosed (incident) and prevalent patients with confirmed IPF diagnosis prospectively.The registry will contribute to the optimization of the management of IPF patients in the long term.

Detailed Description
-----------------
INSIGHTS-IPF will report current and comprehensive data on Idiopathic Pulmonary Fibrosis (IPF) in the long-term. Baseline (cross-sectional part): Description of characteristics of IPF patients in terms of key (socio-) demographic data IPF risk factors, comorbidities methods used for IPF diagnosis IPF disease severity and manifestation (including lung function, cardiopulmonary exercise testing and/or exercise capacity if available, laboratory values, biomarkers) IPF treatment (detailed information on prescribed drugs and doses; non-pharmacological treatment; listing and score for lung transplantation) assessment of patient-related outcomes (PRO) such as quality of life Follow-up (prospectively up to at least 2 years after inclusion): Clinical course of IPF (e.g. in terms of symptoms, lung function, exercise capacity if available) Documentation of treatment pathways (switch/add-on/discontinuation of medication), and of non-pharmacological treatment (e.g. start of long term oxygen therapy; new listing for lung transplantation)Outcomes/events (such as acute respiratory worsening, exacerbations, hospitalisation due to any cause and due to IPF, other complications, survival) Patient-related outcomes such as quality of life, assessed once a year(for comparison with baseline) Resource use for pharmacoeconomic analyses.

Official Title
-----------------
Investigating Significant Health Trends in IPF (INSIGHTS-IPF). Nationwide Prospective Registry.

Conditions
-----------------
Idiopathic Pulmonary Fibrosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: At least 18 years of age Written informed consent for participation in the registry Newly diagnosed (incident) or known (prevalent) IPF (based on diagnosis of treating physician) Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical course of IPF (in terms of symptoms, lung function, survival) |  | up to 5 years after inclusion | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Characteristics of patients with IPF |  | up to 5 years after inclusion | 
| Treatment pathways |  | up to 5 years after inclusion | 
| Functionality and quality of life | St. Georges Respiratory Questionnaire; University of California Shortness of Breath Questionnaire; EuroQuol 5 dimensions | up to 5 years after inclusion | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Clinical routine, Registry, Outcomes, Drug Treatment, Treatment pathways, Survival, Patient-related outcomes, Quality of life, Steroids, Azathioprine, N-Acetylcysteine, Pirfenidone, Tyrosine kinase inhibitors, Nintedanib, multicenter, Germany, Safety, Adverse event